Chiara Gasteiger News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Drug costs and nocebo risks: Navigating the Humira biosimilar boom 1 year later

Drug costs and nocebo risks: Navigating the Humira biosimilar boom 1 year later
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesStanford universityPortola valleySan franciscoMark cubanByrob volanskyKaiser permanenteEric robertsShenaz baghaJohn rp tesserChiara gasteigerInformatics labMark cuban cost plus drug companyBoehringer ingelheimBody labUniversity of california

Biosimilars Month in Review: December 2023

The biosimilars month in review highlights interviews with experts discussing the cost-saving potential of increased biosimilars uptake in the US, a recent US Food and Drug Administration (FDA) approval, and the impact of a mandatory switch to an adalimumab biosimilar in New Zealand.

New zealandYoganand chillarigeLi zhangChiara gasteigerBevacizumab biosimilarDrug administrationUniversity of chicago medicineUniversity of aucklandBiosimilars adoptionChicago medicineAdditional bevacizumabBio thera solutionMedicare advantage

Satisfaction low with mandatory transition from Humira to biosimilar in New Zealand

Satisfaction low with mandatory transition from Humira to biosimilar in New Zealand
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

New zealandShenaz baghaAmgevita amjevitaByjustin cooperChiara gasteigerUniversity of auklandStanford university

Breaking Down Barriers: Why Biosimilars Face Resistance in the US Market

Despite a boom of new, cost-efficient options for chronic conditions, prescriber and patient concern over clinical benefit persists.

United kingdomUnited statesNew zealandPritchettj biosimilarsJessica oomanJuliana reedRusselld cohenAdalimumab biosimilarChiara gasteigerFresenius kabiUniversity of chicago medicineAssociation for accessible medicinesInstitute for human data scienceBiosimilars forumDrug administrationBody lab at stanford university

Patients Unsatisfied After Mandatory Adalimumab Biosimilar Transition

Aotearoa, New Zealand had a mandatory adalimumab biosimilar transition from March – September 2022. A survey reveals low satisfaction with biosimilar’s quality, as well as the lack of alcoholic wipes and a support program.

New zealandUnited kingdomChiara gasteigerUniversity of aucklandAotearoa new zealand